CLINICAL_TRIALS ClinicalTrials.gov record update

A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax®) in Combination With Doxorubicin HCl Liposomal (Doxil®) for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01902225
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:41.289439+00:00
Published At: 2020-06-09T00:00:00+00:00
Record Updated At: 2020-06-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphoma", "T-Cell Lymphoma", "Cutaneous Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-06-09"
protocolSection.identificationModule.nctId: "NCT01902225"
protocolSection.identificationModule.officialTitle: "A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax\u00ae) in Combination With Doxorubicin HCl Liposomal (Doxil\u00ae) for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.